MET as a target in papillary renal cell carcinoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 24812413.
- Also identified by DOI 10.1158/1078-0432.CCR-14-0690.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The biology underlying papillary renal cell carcinoma (pRCC) is largely unknown, and no specific therapies have been developed for advanced disease. The elucidation of the MET pathway status in types I and II pRCC may help to select patients who are more likely to benefit from MET inhibitors.
Medical subject headings
- Carcinoma, Papillary
- Kidney Neoplasms
- Proto-Oncogene Proteins c-met